Mesagut (Mesalazine)

Therapeutic Group : Intestinal Anti-inflammatory Agent

Presentation:

Mesagut Tablet: Each delayed release tablet contains Mesalazine BP 400 mg.

Indications:

– Treatment of mild to moderate Ulcerative Colitis
– Maintenance of remission of mild to moderate Ulcerative Colitis
– Maintenance of remission of Crohn’s disease

Contrainidications:

Mesalazine is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Mesalazine.

Warning & Precautions:

Renal Impairment: Evaluate renal function in all patients prior to initiation and periodically while on mesalazine therapy.
Hepatic Impairment: Evaluate the risks and benefits of using mesalazine in patients with known liver impairment.

Side effects:

The common side effects are nausea, vomiting, dizziness, asthenia, dyspepsia, rash, fatigue, pruritis etc.

Drug interaction:

The concurrent use of mesalazine with known nephrotoxic agents, including NSAIDs may increase the risk of nephrotoxicity & use of mesalazine with azathioprine or 6-mercaptopurine may increase the risk of blood disorder.

Use in special groups:

Pregnant Women: It should be given in pregnancy only if the potential benefit justifies the potential risk to the foetus.
Lactating mother: Caution is advised when it is administered to a nursing women.
Geriatrics: Patients who are 65 years or older, caution should be taken to closely monitor blood cell counts during mesalazine therapy.

Packing:

Mesagut Tablet: Each box contains 30 tablets in alu-alu blister pack.